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The sepsis syndrome represents an improper immune response to infection and is associated with unac-
ceptably high rates of mortality and morbidity. The interactions between T cells and the innate immune system
while combating sepsis are poorly understood. In this report, we observed that treatment with the potent,
antiapoptotic cytokine interleukin-7 (IL-7) accelerated neutrophil recruitment and improved bacterial clear-
ance. We first determined that T cells were necessary for the previously observed IL-7-mediated enhanced
survival. Next, IL-7 increased Bcl-2 expression in T cells isolated from septic mice as early as 3 h following
treatment. This treatment resulted in increased gamma interferon (IFN-) and IP-10 production within the
septic peritoneum together with local and systemic increases of IL-17 in IL-7-treated mice. We further
demonstrate that the increase in IL-17 was largely due to increased recruitment and production by  T cells,
which express CXCR3. Consistent with increased IL-17 production, IL-7 treatment increased CXCL1/KC
production, neutrophil recruitment, and bacterial clearance. Significantly, end-organ tissue injury was not
significantly different between vehicle- and IL-7-treated mice. Collectively, these data illustrate that IL-7 can
mediate the cross talk between Th1 and Th17 lymphocytes during sepsis such that neutrophil recruitment and
bacterial clearance is improved while early tissue injury is not increased. All together, these observations may
underlay novel potential therapeutic targets to improve the host immune response to sepsis.
Sepsis entails a complex immune process involving both the
innate and adaptive immune systems, which can effect concur-
rent changes on the host (39, 56). The immune response to
infection is typically modeled by phagocytic cells as first re-
sponders for the early removal of pathogenic bodies, while the
adaptive system becomes involved later for mop-up duty and
maintenance of a long-term immune response against the cur-
rent pathogens. Recent literature suggests an early role for the
adaptive immune system in mediating sepsis (30); however, a
paucity of effective sepsis therapies suggests a gap in our
knowledge concerning cross talk and the respective roles of the
adaptive and innate immune during the host response to sep-
sis. An increased understanding of the complex interplay of
these immune response arms is critical, given the annual toll
this diagnosis places on both human life and health care dollars
(2, 41).
 T cells represent a small subset of cells with a restricted
T-cell receptor (TCR) repertoire of ligands. These cells are
widespread in epithelium-rich tissues such as the skin and
intestine, with cytokine production dictated by the tissues in
which they reside (8, 12, 20, 40, 54). Contradictory results have
been published on the role of  T cells during sepsis, suggest-
ing that these cells become more pathogenic as the severity of
the sepsis model used increases (6, 10, 13). Our previous report
demonstrates that  T cells play a key role in neutrophil
recruitment to the site of infection and control of bacterial load
following cecal ligation and puncture (CLP). Recently,  T
cells have been implicated as the major producer of the cyto-
kine interleukin-17 (IL-17) during sepsis (13). IL-17A is part of
the IL-17 family of cytokines, produced by diverse cell popu-
lations such as conventional CD4 and CD8 T cells as well as 
T cells (58). While the protective or pathogenic role of IL-17 in
sepsis is not yet clear (13, 16), it is known that IL-17 mediates
recruitment of myeloid cells through downstream production
of CXCL1/KC and CXCL2/MIP-2, presumably through the
stabilization of mRNA (18). Additionally, the IL-17 receptor
(IL-17R) is necessary for neutrophil recruitment to the site of
infection and control of bacterial load following CLP (16). The
functions of IL-17 on myeloid cell recruitment, along with its
production by T cells during sepsis, make this cytokine an
interesting target in mediating the cross talk that occurs be-
tween the innate and adaptive responses to sepsis.
The suggestion of early cross talk between the innate and
adaptive immune responses extends from recent reports, indi-
cating the necessity of T cells in bacterial clearance following
infection (29, 37, 54, 55). Additionally, T-cell activation was
newly linked to bacterial clearance through increased neutro-
phil oxidative burst and phagocytosis (29). These findings pro-
vide a bridge to the literature, demonstrating worsened out-
comes in septic T-cell-deficient mice (26) that are reversed
with adoptive transfer of T cells (47). Further, it is known that
T cells undergo apoptosis within the first 24 h after onset of
sepsis (25, 27, 57), and the degree of apoptosis correlates with
* Corresponding author. Mailing address: MSB SRU G479 ML
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the sepsis severity (24, 33). Additionally, remaining T cells
demonstrate reduced functionality illustrated by decreased
production of gamma interferon (IFN-) (28). Taken together,
these results provide mechanistic insight into how prevention
of T-cell apoptosis improves survival in a murine model of
sepsis (26) and illustrate a therapeutic avenue for reduction of
morbidity and mortality associated with this disease process.
The cytokines IL-2, IL-7, and IL-15 are ligands for the cy-
tokine receptor common gamma chain. The IL-7 receptor is
expressed mainly on T lymphocytes, with IL-7 playing a key
role in T-cell differentiation, survival, and proliferation (36).
Recently, we observed that IL-7 treatment significantly re-
duced T-cell apoptosis in the spleen and mesenteric lymph
nodes following sepsis (55). Additionally, we reported that
treatment with recombinant human IL-7 (rhIL-7) improved
the delayed-type hypersensitivity (DTH) response while par-
tially preventing a sepsis-induced decrease in T-cell IFN-
production (55). The attenuation of T-cell apoptosis and im-
proved functionality following rhIL-7 treatment were associ-
ated with improved survival (55). To build upon our previous
study, we undertook investigations to further determine how
IL-7 stabilization of T-cell numbers and function mediated
tissue injury, bacterial load, and the neutrophil response dur-
ing sepsis. Here, we found that IL-7 treatment significantly
accelerated  T-cell recruitment to the site of infection, such
that the bacterial load was decreased. Significantly, we postu-
late that the early IL-7 stabilization of the adaptive immune
response allows for a more beneficial innate immune response
during sepsis.
MATERIALS AND METHODS
Cecal ligation and puncture. Male C57BL/6 (wild-type [WT]) mice between 6
and 8 weeks of age (20 to 28 g), TCR /-deficient mice (B6.129P2-
Tcrbtm1MOM Tcrdtm1MOM/J; Jackson Laboratory, Bar Harbor, ME), and TCR
-deficient mice (B6.129P2-Tcrdtm1Mom/J; Jackson Laboratory) were utilized.
All experiments involving animals were performed under protocols approved by
the Institutional Animal Care and Use Committee (IACUC) of the University of
Cincinnati. Polymicrobial sepsis was induced as previously described (9). Briefly,
cecal ligation and puncture (CLP) operations were always performed between
6 a.m. and 10 a.m. Normal fed mice were anesthetized to effect by 2.5% isoflu-
rane in oxygen via face masks. After laparotomy, the latter 80% of the cecum was
ligated and punctured once on the antimesenteric side with a 23-gauge needle. A
small amount of bowel content was extruded through the puncture hole to ensure
full thickness of the perforation. The cecum was replaced in its original location,
and the midline incision was closed by a two-layer suture. Prior to closure of the
peritoneum with one figure-of-eight stitch, 5 g human recombinant IL-7
(Cytheris, Issy-les-Moulineaux, France) or an equivalent volume of vehicle was
injected via pipette. Sham-operated animals received midline laparotomies, ex-
teriorization of the cecum with prompt replacement, and closure of incisions in
two layers. The animals were resuscitated with 1 ml of sterile saline subcutane-
ously and kept on a heating blanket, with additional oxygen supply for 1 h. In
survival studies, animals were given ad libitum access to food and water and
followed until death or humane sacrifice per protocol. Animals were evaluated
every 12 h following CLP.
Flow cytometry for surface and intracellular staining. Analyses of cell surface
antigen expression and in situ cytokine and Bcl-2 expression were performed as
previously described (5) on spleen and peritoneal lavage samples. Flow cytom-
etry data acquisition and analysis were performed on an LSR II using FACS Diva
software (BD Biosciences, Mountain View, CA). The antibodies used were CD4
(clone RM4-5; BioLegend, San Diego, CA), CD8 (clone 53-6.7; BD Biosciences,
San Diego, CA), CD69 (clone H1.2F3; BD Biosciences), CD44 (clones Pgp-1
and Ly-24; BD Biosciences), CD62L (clone MEL-14; Invitrogen, Carlsbad, CA),
 T cell (clone H57-597),  T cell (clone GL3; BioLegend), CXCR3 (clone
49801; R&D, Minneapolis, MN), Bcl-2 (clone 3F11; BD Biosciences), IL-17A
(clone TC11-18H10.1; BioLegend), CD11b (clone M1/70; BD Biosciences), and
Gr-1/Ly6G (clone 1A8; BD Biosciences). Leukocyte subsets were defined as
follows: CD4 naive (CD62Lhi CD44lo), CD4 central memory (CD62Lhi
CD44hi), CD4 effector memory (CD62Llo CD44hi), CD8 naive (CD62Lhi
CD44lo), CD8 central memory (CD62Lhi CD44hi), CD8 effector memory
(CD62Llo CD44hi), and neutrophils (Gr-1hi CD11b).
Bacterial load determination. Bacterial load determination was performed
with blood samples harvested aseptically by cardiac puncture as previously de-
scribed (54). Samples were serially diluted in sterile saline and cultured on soy
agar pour plates. Plates were incubated at 37°C for 24 h, and colony enumeration
was performed.
Cytokine and chemokine measurements by ELISA. Whole-blood samples were
harvested by sterile cardiac punching, and sera were isolated using serum sepa-
rator tubes. Peritoneal lavage fluid and cells were obtained by injection of 9 ml
0.9% normal saline intraperitoneally and removal via syringe. IL-6 (Invitrogen),
IFN- (Invitrogen), CXCL1/KC (R&D), IL-17 (eBioscience, San Diego, CA),
and CXCL10/IP-10 (Peprotech, Rocky Hill, NJ) levels were analyzed by enzyme-
linked immunosorbent assay (ELISA), according to the manufacturers’ protocol.
Phagocytosis determination. Cells from peritoneal lavage fluid were harvested
24 h after CLP and mixed with opsonized Alexa Fluor 488-labeled Escherichia
coli (K-12 strain; Invitrogen). This suspension was incubated at 37°C for 5 min.
This time point was chosen based upon previous optimization experiments.
Following the incubation period, unattached extracellular bacteria were removed
by being washed three times. Samples were run on a Becton Dickinson LSR II
to determine the mean fluorescence intensity (MFI), a measure of the number of
bacteria taken up per cell. To quench the fluorescence of adherent bacteria,
trypan blue was added 1 min before the second acquisition. Quenching with
trypan blue reduced the fluorescein isothiocyanate (FITC) fluorescence of ad-
herent bacteria by excitation energy transfer (21).
Neutrophil oxidative burst assay. The oxidative burst was determined as
previously described (48). Briefly, polystyrene tissue culture dishes were coated
with 1 g/well fibronectin for 2 h at 37°C and 5% CO2 and then washed. A total
of 100 l of reaction mixture (10 mM scopoletin, 1 mg/ml horseradish peroxi-
dase, 4 mM NaN3 in Krebs-Ringer phosphate buffer [KRPG]) and 20 l neu-
trophils resuspended in KRPG at 7.5  105 cells/ml were allowed to incubate for
10 min at 37°C in the wells prior to stimulation with either buffer or N-formyl-
methionyl-leucyl-phenylalanine (fMLP; 100 nM). Fluorescence was measured
immediately and at 10-min intervals for 60 min. H2O2 production was calculated
from the decrease in fluorescence due to oxidation of scopoletin. The data are
expressed as nanomoles of H2O2 produced per 1.5  104 polymorphonuclear
leukocytes (PMNs).
Tissue injury determination. For general tissue damage assessment, serum
samples were obtained as described above, diluted 1:4, and run for the aspartate
transaminase (AST) level on the Siemens Dimension Xpand Plus integrated
chemistry system (Siemens Healthcare Diagnostics, Deerfield, IL). Lung tissue
(100 mg) was homogenized in 2 ml buffer A (3.4 mM KH2HPO4 and 16 mM
Na2HPO4, pH 7.4). After centrifugation for 20 min at 10,000  g, the pellet was
resuspended in 10 vol buffer B (43.2 mM KH2HPO4, 6.5 mM Na2HPO4, 10 mM
EDTA, and 0.5% hexadecyltrimethylammonium, pH 6.0) and was sonicated for
10 s. After being heated for 2 h at 60°C, the supernatant was reacted with
3,3,5,5-tetramethylbenzidine (Sigma Chemical Co., St. Louis, MO), and the
optical density (OD) at 655 nm was determined. Two-centimeter sections of
intestine were harvested and placed on previously weighed trays. Samples were
incubated at 55°C for 72 h and reweighed. They were incubated for another 24 h
at 55°C and reweighed to ensure complete fluid evaporation. The wet weight-
to-dry weight ratio was then calculated.
Statistical analyses. Statistical comparisons were performed using the
Kaplan-Meier log rank test (survival), Student t test (two groups), or one-way
analysis of variance (ANOVA) with the Holm-Sidak post hoc test (more than
two groups), using StatView 3.5 (SAS Institute, Cary, NC) and GraphPad
Prism 5.0 (GraphPad Software, La Jolla, CA). The mean and standard error
of the mean were calculated in experiments containing multiple data points.
A P value of 0.05 was considered statistically significant.
RESULTS
Previously, we demonstrated enhanced survival in septic
wild-type mice treated with recombinant human IL-7 at the
time of CLP (54). To confirm the requirement for  and 
T cells for the rhIL-7-mediated survival advantage during sep-
sis, we subjected mice deficient in these cells treated with
either rhIL-7 or vehicle and then monitored them for survival.
Here, we observed no differences in survival or median survival
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times (Fig. 1). All together, these data implicate the necessity
of  and/or  T cells for the IL-7-induced increase in survival
of septic wild-type mice.
A signature hallmark of sepsis is the profound and rapid
depletion of lymphocytes (23). T-cell apoptosis has been re-
ported as the underlying cause of decreased lymphocyte num-
bers following sepsis (27, 60). Previously, we observed that
splenic T cells isolated from rhIL-7-treated mice had increased
Bcl-2 expression as well as reduced T-cell apoptosis at 24 h
after CLP. As increased expression of Bcl-2 at 24 h after CLP
may represent a selection bias of surviving lymphocytes, we
sought to elucidate the effect of rhIL-7 on T-cell Bcl-2 expres-
sion at 3 h after sepsis induction, when cells have not yet
undergone significant depletion. Here, we determined that
IL-7 treatment resulted in increased Bcl-2 expression in naive
CD4 and CD8 T cells and effector memory CD4 T cells com-
pared to that in T cells isolated from vehicle-treated septic
mice (Fig. 2A to D). Thus, rhIL-7 treatment can begin to
enhance T-cell survival quite early after treatment.
IL-7 treatment enhances IFN- and IP-10 production dur-
ing sepsis. IFN- is a key cytokine in the host immune re-
FIG. 3. IL-7 treatment enhances IFN- levels in the septic perito-
neum. CLP-operated WT mice were treated with 5 g human recom-
binant IL-7 or vehicle at the time of CLP. IFN- was measured by
ELISA in peritoneal samples obtained 3 h following CLP. The sample
size was 8 mice/group. Data are expressed as the mean values 	 SEM.
*, P 
 0.05.
FIG. 1. Effects of IL-7 on survival following sepsis are mediated by
TCR  or TCR  cells. Combined TCR /-deficient mice were
treated with 5 g human recombinant IL-7 or vehicle at the time of
CLP and then monitored for survival. The sample size was 10 to 11
mice/group. Data are presented as a Kaplan-Meier survival curve.
FIG. 2. IL-7 treatment elevates CD4 and CD8 lymphocyte Bcl-2 expression as early as 3 h after CLP. Sham- and CLP-operated WT mice were
treated with 5 g human recombinant IL-7 or vehicle (VEH) at the time of CLP. Splenocytes obtained 3 h after CLP were directly analyzed by
flow cytometry for Bcl-2 expression on naive CD4 (A), effector memory (EM) CD4 (B), naive CD8 (C), and EM CD8 (D) T-cell subsets.
Naive T cells had CD62Lhi CD44lo expression, while EM T cells had CD62Llo CD44hi expression. The sample size was 4 mice/group. Data are
expressed as the mean values 	 SEM. *, P 
 0.05; **, P 
 0.01; ***, P 
 0.001.
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sponse to sepsis, as evidenced by decreased survival of IFN-
knockout mice subjected to CLP compared to that of WT mice
(37). Here, we observed increased peritoneal IFN- concen-
trations in rhIL-7-treated mice at almost double the level
found in vehicle-treated animals (Fig. 3). Sham levels were
undetectable, as were serum levels of IFN- at this time point
(data not shown). Of the many roles IFN- can play during the
immune response, one involves stimulating the release of
CXCL10/IP-10 by macrophages (52). CXCL10/IP-10 is one
ligand for CXCR3. It has been previously reported that  T
cells can express CXCR3 and that this receptor can mediate
recruitment (1). Therefore, we evaluated the CXCR3 ligand in
WT mice following CLP and observed its expression upon 89%
of peritoneal  T cells (Fig. 4A). Additionally, we demon-
strated an approximately 2-fold increase in CXCL10/IP-10 in
the rhIL-7-treated mice versus that in the vehicle-treated mice,
while sham mice had no appreciable levels of this ligand (Fig.
4B). Thus, rhIL-7 treatment, possibly through prevention of
T-cell apoptosis, enhances peritoneal levels of IFN- with a
subsequent downstream increase in CXCL10/IP-10 produc-
tion.
Neutrophil recruitment, but not activation or functionality,
is accelerated by rhIL-7 treatment. Neutrophils clear bacterial
pathogens during sepsis as part of a complex process involving
recruitment to the site of infection, activation, cytokine secre-
tion, phagocytosis, and oxidative burst killing of bacteria. Here,
we evaluated the enumeration, activation, and functionality of
neutrophils found at the site of infection at multiple time
points following CLP. Treatment of mice with rhIL-7 caused
an accelerated recruitment to the peritoneum at 6 h following
CLP compared to that of vehicle-treated mice, with no differ-
ence between groups seen at 24 h (Fig. 5A). CD11b expression
was used as a surrogate marker for neutrophil activation and
FIG. 4. CXCR3 expression on peritoneal TCR  cells. (A) Flow
cytometric analysis of WT peritoneal TCR  cells obtained 3 h fol-
lowing CLP-evaluated CXCR3 expression. The sample size was 4
mice/group. (B) Sham- and CLP-operated WT mice were treated with
5 g human recombinant IL-7 or vehicle at the time of CLP. Perito-
neal lavage fluid obtained 3 h after CLP was analyzed by ELISA for
CXCL10/IP-10. The sample size was 4 mice/group. Data are expressed
as the mean values 	 SEM. ^, P
 0.01 compared to sham groups; &,
P 
 0.01 compared to all groups; PE-A, phycoerythrin; APC-A,
allophycocyanin.
FIG. 5. IL-7 treatment enhances neutrophil recruitment but not activation or functionality during sepsis. CLP-operated WT mice were treated
with 5 g human recombinant IL-7 or vehicle at the time of CLP. Neutrophils at the site of infection were analyzed by flow cytometry for
enumeration (A) and determination of CD11b expression (B) at the indicated times following CLP. The sample size was 9 to 13 mice/group at
6 h and 12 to 13 mice/group at 24 h. Neutrophil functionality was evaluated using phagocytosis (C) and oxidative burst (D) at the indicated time
points. The sample size was 6 mice/group at 3 h and 4 mice/group at 6 h. Data are expressed as the mean values 	 SEM. **, P 
 0.01.
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showed no difference between WT and rhIL-7-treated mice at
6 or 24 h following CLP (Fig. 5B) or between sham animals
treated with rhIL-7 and phosphate-buffered saline (PBS) (data
not shown). Lastly, we evaluated the phagocytosis and oxida-
tive burst potential of neutrophils obtained from the site of
infection at 6 h and 24 h following CLP in WT and rhIL-7-
treated mice. Interestingly, we found no differences in either
phagocytosis (Fig. 5C) or oxidative burst (Fig. 5D) between the
two groups at either time point. These findings suggest that
rhIL-7 plays a singular role in neutrophil recruitment to the
site of infection during sepsis.
rhIL-7 treatment increased  T-cell numbers, IL-17 pro-
duction, and CXCL1/KC production. Neutrophil recruitment
can be mediated by IL-17 and subsequent production of
CXCL1/KC. During sepsis,  T cells have been reported to be
significant producers of IL-17 (13) and can play a critical role
in increasing peritoneal neutrophil accumulation (54). In pilot
experiments, we were unable to observe significant numbers of
peritoneal  T cells in sham animals. Following CLP, we
determined that rhIL-7 treatment resulted in both increasing
the numbers of IL-17-producing  T cells and enhancing
IL-17 production (Fig. 6A and B). To confirm the necessity of
 T cells for IL-7-induced enhancement of IL-17 during sep-
sis, we subjected wild-type and  T-cell-deficient mice to CLP
with and without rhIL-7 treatment. Evaluation of the perito-
neal lavage fluid at 6 h following the injury demonstrated
significantly elevated IL-17 only in WT mice treated with
rhIL-7 compared to that in all other treatment groups (Fig.
6C). Lastly, a positive correlation between neutrophil recruit-
ment and CXCL1/KC expression has been reported (17, 34, 44,
51, 59). As IL-7 treatment increased neutrophil numbers at the
site of infection, we next evaluated local levels of CXCL1/KC
and observed significantly increased CXCL1/KC in the perito-
neal lavage fluid of rhIL-7-treated mice compared to that in
the peritoneal lavage fluid of WT mice (Fig. 6D). Thus, treat-
ment with rhIL-7 rapidly increases the number of peritoneal 
T cells present following sepsis, the production of IL-17 by
these cells, and increased CXCL1/KC accumulation.
rhIL-7 treatment increases inflammation and bacterial
clearance without changing end-organ tissue injury. Properly
regulated neutrophils play an important role in bacterial clear-
ance (32); however, decreased apoptosis and increased half-
life may result in increased tissue injury during sepsis (22).
During sepsis, an optimal balance among early pathogen clear-
ance, associated inflammation, and end-organ tissue damage
will likely allow for a reduction of host morbidity and mortality.
As IL-6 has previously been utilized as a surrogate marker for
inflammation (42), we evaluated the serum levels of this cyto-
kine at 6 and 24 h. Mice treated with rhIL-7 had significantly
higher serum IL-6 levels at 6 h than WT mice, with no differ-
ence existing at 24 h (Fig. 7A). Evaluation of bacteremia at
24 h following CLP demonstrated a significantly lower bacte-
rial load in those animals treated with rhIL-7 rather than
vehicle (Fig. 7B), consistent with previous findings. We next
evaluated general, lung, and intestine tissue injury. We ob-
served that serum aspartate aminotransferase (AST) levels
(Fig. 7C), lung myeloperoxidase (MPO) levels (Fig. 7D), bron-
choalveolar lavage (BAL) fluid protein content (data not
shown), and intestinal wet/dry ratios (Fig. 7E) were not signif-
icantly different between vehicle-treated WT mice and those
treated with rhIL-7. Experiments conducted with sham-oper-
ated mice did not demonstrate detectable levels of IL-6, bac-
teremia, or tissue injury. All together, mice treated with rhIL-7
had diminished bacteremia and early increased, but not sus-
tained, inflammation, but not worsened tissue damage, com-
pared to those of vehicle-treated mice.
DISCUSSION
In this study, we tested the hypothesis that IL-7, a potent
T-cell antiapoptotic cytokine, would mediate the early innate
immune response to sepsis. First, we demonstrated the neces-
sity of  and/or  T cells for the IL-7-induced increase in
survival of septic wild-type mice. Additionally, we show the
upregulation of Bcl-2 expression on CD4 T cells as early as 3 h
following CLP in mice treated with rhIL-7. Here, mice treated
with rhIL-7 were shown to have increased neutrophil recruit-
ment to the peritoneum without increased end-organ tissue
damage compared to that of WT controls. Elevated neutrophil
recruitment at the site of infection was correlated with elevated
local and systemic production of CXCL1/KC and IL-17. We
determined that following rhIL-7 treatment, septic mice had
increased numbers of  T cells in the peritoneum, producing
elevated amounts of IL-17. Additionally,  T cells were nec-
essary for an elevated peritoneal IL-17 concentration following
IL-7 treatment. Previously, we demonstrated that T cells iso-
lated from IL-7-treated mice had a reversal of the sepsis-
FIG. 6. IL-7 treatment increases the number of, and IL-17 produc-
tion by, peritoneal  T cells following CLP. CLP-operated WT mice
were treated with 5 g human recombinant IL-7 or vehicle at the time
of CLP. Flow cytometric analysis was used to enumerate the number of
peritoneal  T cells producing IL-17 (A) and the intensity of IL-17
expression by peritoneal  T cells (B) 3 h after CLP. The sample size
was 4 mice/group. (C) Peritoneal lavage fluid obtained 6 h after CLP
from WT and TCR -deficient mice treated with IL-7 or vehicle was
analyzed by ELISA for IL-17. The sample size was 5 mice/group.
(D) Peritoneal lavage fluid obtained 6 h after CLP was analyzed by
ELISA for CXCL1/KC. The sample size was 11 to 14 mice/group. Data
are expressed as the mean values 	 SEM. *, P 
 0.05; **, P 
 0.01.
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induced defective production of IFN- (55). Here, we built
upon these findings by demonstrating an IL-7-induced increase
in peritoneal IFN- levels. Increased IFN- production has
been shown to promote macrophage or endothelial CXCL10/
IP-10 expression (3, 19, 31), a ligand for the CXCR3 receptor.
We show that this receptor is expressed upon  T cells. These
results suggest that IL-7 treatment improves the host response
to sepsis through the rapid recruitment of  T cells to the site
of infection, coupled with accelerated  T cell-mediated re-
cruitment of neutrophils to the site of infection. All together,
these data are summarized in Fig. 8.
The work detailing that rhIL-7 treatment improves the mu-
rine host response to sepsis has recently been reported (55),
although its effects on lymphocyte apoptosis and proliferation
in human diseases such as hepatitis C and cancer stem from
ongoing clinical trials (46, 49). At 24 h following CLP, IL-7
treatment significantly increased Bcl-2 expression in splenic
CD4 and CD8 T-cell subsets compared to that in wild-type
animals and produced a relative change of mRNA abundance
in CD4 T cells (55). Additionally, rhIL-7 blunted both splenic
and mesenteric lymph node T-cell apoptosis at 24 h following
CLP, resulting in significantly elevated numbers of CD4 and
CD8 T cells in treated versus WT mice at this time point (55).
Clinical findings of decreased Bcl-2 gene expression in septic
human patients at 12 and 24 h following diagnosis were pre-
viously noted to correlate highly with decreased absolute num-
bers of CD4 lymphocytes (4, 24). Furthermore, prevention of
apoptosis with overexpression of Bcl-2 is known to prevent
T-cell apoptosis, providing protection from sepsis-related mor-
FIG. 7. IL-7 treatment mediates serum IL-6 levels, decreases bacteremia, and does not alter tissue injury after CLP. WT mice were subjected
to CLP, as indicated in Materials and Methods, and treated with 5 g human recombinant IL-7 or vehicle at the time of CLP. (A) Sera obtained
at the indicated time points were analyzed by ELISA for IL-6. (B) Serum bacterial loads were measured 24 h after induction of sepsis. (C) Serum
AST levels were measured 24 h after induction of sepsis. (D) Lungs were harvested at the indicated times after CLP, and MPO was measured.
(E) Sections (2 cm) of terminal ileum were obtained at the indicated times following CLP, weighed, and dried as described in Materials and
Methods. The sample size was 8 to 11 mice/group. Data are expressed as the mean values 	 SEM. *, P 
 0.05; ***, P 
 0.001.
FIG. 8. Model for IL-7’s role in modulating neutrophil recruitment
in sepsis. This figure represents a schematic hypothesis, demonstrating
how rhIL-7 treatment, through maintenance of appropriate T-cell im-
munocompetence, results in enhanced neutrophil recruitment to the
site of infection.




arch 26, 2014 by W







tality (26). Here, we show that naive CD4, CD8, and effector
memory CD4 cells obtained from rhIL-7-treated animals have
significantly elevated Bcl-2 protein expression at 3 h following
CLP, suggesting that apoptotic signaling in T cells takes place
soon after induction of sepsis. One key effect of early T-cell
apoptosis in sepsis is reduced immunocompetence through
decreased IFN- production. The production of IFN- by CD4
T cells during sepsis is associated with improved survival, de-
creased bacterial load, and increased neutrophil functionality
(37, 53). Interestingly, we show that IL-7 treatment signifi-
cantly increases the peritoneal concentration of IFN- as early
as 3 h following CLP. These data suggest that rhIL-7 treatment
upregulates Bcl-2 expression very soon after treatment, such
that T-cell apoptosis can be reduced and IFN- production can
be preserved.
The enhanced production of IFN- in rhIL-7-treated mice
relative to WT controls exerts downstream effects on both
adaptive and innate cells. Gamma interferon-inducible protein
10 (CXCL10/IP-10) is a chemokine secreted by endothelial
cells, macrophages, and neutrophils upon stimulation with
IFN- and serves as a chemoattractant for T lymphocytes (7,
35, 61). It has been suggested that CXCL10/IP-10 plays a
distinct role in the recruitment of T cells expressing CXCR3 to
sites of inflammation (7), consistent with findings that TCR 
T cells express CXCR3 and transmigrate upon stimulation with
IP-10 (11, 45). Here, we demonstrate that a large percentage of
 T cells and neutrophils present at the site of infection soon
following CLP express CXCR3. Further, septic mice treated
with IL-7 had significantly larger amounts of CXCL10/IP-10 at
the peritoneum. Consistent with these findings, we observed
that rhIL-7 treatment resulted in an elevated number of  T
cells at the site of infection. All together, we postulate that IL-7
treatment enhanced T-cell IFN- production such that
CXCL10/IP-10 was increased and  T cells entered the site of
infection.
After exposure to CXCL10/IP-10,  T cells can transmi-
grate and mediate inflammatory processes in tissue compart-
ments such as the lung and peritoneum. The inflammatory
effects of  T cells result, in part, from production of the
cytokine IL-17 in response to early and sustained stimulation
by IL-1, TLR-2, and IL-23 (1, 38, 43, 50). IL-17 acts upon
mesothelial cells to produce CXCL1/KC and CXCL2/MIP-2
(15) and has been shown to be necessary for the promotion of
granulopoiesis and neutrophil recruitment in peripheral tissues
(14, 62). Here, we show that local and systemic levels of IL-17
are elevated with rhIL-7 treatment following CLP, with a sub-
sequent and complementary increase in CXCL1/KC. Further,
elevated IL-17 following rhIL-7 treatment in sepsis is depen-
dent upon the presence of  T cells. This demonstrates a
sequential and mechanistic pathway through which rhIL-7-
mediated attenuation of T-cell dysfunction results in increased
neutrophil recruitment to the site of infection following CLP.
The elevated number of neutrophils early in the septic course
is likely responsible for the decreased bacterial load in rhIL-
7-treated mice, even in the absence of neutrophil functionality
changes. The rapid return of neutrophil numbers to WT levels
at 24 h may explain the comparable levels of end-organ tissue
damage seen in these groups, consistent with previous findings
in this model assessing the role of neutrophils in sepsis (22).
The lack of a functional effect on neutrophils following IL-7
treatment may further explain the consonant end-organ results
in these studies. All together, we speculated that the ability of
rhIL-7 to maintain numbers and functionality of CD4 T cells
following sepsis resulted in accelerated  T-cell recruitment
and functionality at the site of infection, ultimately aiding bac-
terial clearance without worsening tissue damage.
Our data reported here demonstrate that rhIL-7 treatment
increased peritoneal IFN- levels, IP-10 levels, and CXCR3-
expressing  T-cell accumulation. However, one limitation to
this report is a lack of data verifying that IP-10, through
CXCR3, recruits  T cells to the peritoneum. While trying to
address this, we subjected CXCR3-deficient mice to CLP and
found that these mice had significantly increased peritoneal
bacterial loads compared to those of WT mice. In addition,
neutrophils isolated from these mice demonstrated a de-
creased phagocytic capacity. Finally, the CXCR3 knockout
(KO) had increased numbers of neutrophils and macrophages
at the site of infection compared to those of controls. We
speculate that the CXCR3-mediated defect in phagocytosis
resulted in sustained leukocyte chemotaxis that ultimately con-
founded the experimental results. Thus, the use of more spe-
cific reagents will be needed to fully address this potentially
important mechanism.
Sepsis involves a complex interplay between the innate and
adaptive immune systems that occurs very early after the onset
of disease and not in a delayed fashion, as previously accepted.
 T cells, through production of IL-17, appear to play a
central role in immune response cross talk between the two
arms of the immune response. In addition, the existence of
cross talk between these two responses suggests that multiple
targets for future therapeutic intervention may be available.
One such therapeutic target is the cytokine IL-7, shown to play
a direct role in prevention of T-cell apoptosis, with subsequent
downstream effects resulting in an enhanced innate response
to sepsis. Going forward, these insights may play a role in the
ultimate production of a viable sepsis therapeutic target that
reduces the health care burden imposed by this disease process.
ACKNOWLEDGMENTS
This work was supported in part by National Institutes of Health
grants GM72760 (to C.C.C.), GM44118 and GM55194 (to R.S.H.),
and AI057753 (to D.A.H.) and by the Alan A. and Edith L. Wolff
Foundation. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Michel Morre is the CEO of Cytheris Corporation, a company that
makes IL-7 for clinical trials. The other authors have no financial
conflicts of interest.
REFERENCES
1. Ajuebor, M. N., Y. Jin, G. L. Gremillion, R. M. Strieter, Q. Chen, and P. A.
Adegboyega. 2008. GammadeltaT cells initiate acute inflammation and injury
in adenovirus-infected liver via cytokine-chemokine cross talk. J. Virol. 82:
9564–9576.
2. Angus, D. C., W. T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and
M. R. Pinsky. 2001. Epidemiology of severe sepsis in the United States:
analysis of incidence, outcome, and associated costs of care. Crit. Care Med.
29:1303–1310.
3. Bacon, K. B., and J. J. Oppenheim. 1998. Chemokines in disease models and
pathogenesis. Cytokine Growth Factor Rev. 9:167–173.
4. Bilbault, P., T. Lavaux, A. Lahlou, B. Uring-Lambert, M. P. Gaub, C.
Ratomponirina, N. Meyer, P. Oudet, and F. Schneider. 2004. Transient Bcl-2
gene down-expression in circulating mononuclear cells of severe sepsis pa-
tients who died despite appropriate intensive care. Intensive Care Med.
30:408–415.
5. Caldwell, C. C., H. Kojima, D. Lukashev, J. Armstrong, M. Farber, S. G.




arch 26, 2014 by W







Apasov, and M. V. Sitkovsky. 2001. Differential effects of physiologically
relevant hypoxic conditions on T lymphocyte development and effector func-
tions. J. Immunol. 167:6140–6149.
6. Chung, C. S., L. Watkins, A. Funches, J. Lomas-Neira, W. G. Cioffi, and A.
Ayala. 2006. Deficiency of gammadelta T lymphocytes contributes to mor-
tality and immunosuppression in sepsis. Am. J. Physiol. Regul. Integr. Comp.
Physiol. 291:R1338–R1343.
7. Dufour, J. H., M. Dziejman, M. T. Liu, J. H. Leung, T. E. Lane, and A. D.
Luster. 2002. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient
mice reveal a role for IP-10 in effector T cell generation and trafficking.
J. Immunol. 168:3195–3204.
8. Duhindan, N., A. J. Farley, S. Humphreys, C. Parker, B. Rossiter, and C. G.
Brooks. 1997. Patterns of lymphokine secretion amongst mouse gamma delta
T cell clones. Eur. J. Immunol. 27:1704–1712.
9. Ebong, S. J., D. R. Call, G. Bolgos, D. E. Newcomb, J. I. Granger, M.
O’Reilly, and D. G. Remick. 1999. Immunopathologic responses to non-
lethal sepsis. Shock 12:118–126.
10. Enoh, V. T., S. H. Lin, C. Y. Lin, T. Toliver-Kinsky, E. D. Murphey, T. K.
Varma, and E. R. Sherwood. 2007. Mice depleted of alphabeta but not
gammadelta T cells are resistant to mortality caused by cecal ligation and
puncture. Shock 27:507–519.
11. Ferrero, E., P. Biswas, K. Vettoretto, M. Ferrarini, M. Uguccioni, L. Piali,
B. E. Leone, B. Moser, C. Rugarli, and R. Pardi. 2003. Macrophages exposed
to Mycobacterium tuberculosis release chemokines able to recruit selected
leucocyte subpopulations: focus on gammadelta cells. Immunology 108:365–
374.
12. Ferrick, D. A., M. D. Schrenzel, T. Mulvania, B. Hsieh, W. G. Ferlin, and H.
Lepper. 1995. Differential production of interferon-gamma and interleukin-4
in response to Th1- and Th2-stimulating pathogens by gamma delta T cells
in vivo. Nature 373:255–257.
13. Flierl, M. A., D. Rittirsch, H. Gao, L. M. Hoesel, B. A. Nadeau, D. E. Day,
F. S. Zetoune, J. V. Sarma, M. S. Huber-Lang, J. L. Ferrara, and P. A. Ward.
2008. Adverse functions of IL-17A in experimental sepsis. FASEB J. 22:
2198–2205.
14. Forlow, S. B., J. R. Schurr, J. K. Kolls, G. J. Bagby, P. O. Schwarzenberger,
and K. Ley. 2001. Increased granulopoiesis through interleukin-17 and gran-
ulocyte colony-stimulating factor in leukocyte adhesion molecule-deficient
mice. Blood 98:3309–3314.
15. Fossiez, F., O. Djossou, P. Chomarat, L. Flores-Romo, S. Ait-Yahia, C.
Maat, J. J. Pin, P. Garrone, E. Garcia, S. Saeland, D. Blanchard, C. Gail-
lard, B. Das Mahapatra, E. Rouvier, P. Golstein, J. Banchereau, and S.
Lebecque. 1996. T cell interleukin-17 induces stromal cells to produce proin-
flammatory and hematopoietic cytokines. J. Exp. Med. 183:2593–2603.
16. Freitas, A., J. C. Alves-Filho, T. Victoni, T. Secher, H. P. Lemos, F. Sonego,
F. Q. Cunha, and B. Ryffel. 2009. IL-17 receptor signaling is required to
control polymicrobial sepsis. J. Immunol. 182:7846–7854.
17. Frink, M., Y. C. Hsieh, C. H. Hsieh, H. C. Pape, M. A. Choudhry, M. G.
Schwacha, and I. H. Chaudry. 2007. Keratinocyte-derived chemokine plays
a critical role in the induction of systemic inflammation and tissue damage
after trauma-hemorrhage. Shock 28:576–581.
18. Gaffen, S. L. 2009. Structure and signalling in the IL-17 receptor family. Nat.
Rev. Immunol. 9:556–567.
19. Han, C., J. Fu, Z. Liu, H. Huang, L. Luo, and Z. Yin. 2010. Dipyrithione
inhibits IFN-gamma-induced JAK/STAT1 signaling pathway activation and
IP-10/CXCL10 expression in RAW264.7 cells. Inflamm. Res. 59:809–816.
20. Hayday, A., and R. Tigelaar. 2003. Immunoregulation in the tissues by
gammadelta T cells. Nat. Rev. Immunol. 3:233–242.
21. Hed, J. 1986. Methods for distinguishing ingested from adhering particles.
Methods Enzymol. 132:198–204.
22. Hoesel, L. M., T. A. Neff, S. B. Neff, J. G. Younger, E. W. Olle, H. Gao, M. J.
Pianko, K. D. Bernacki, J. V. Sarma, and P. A. Ward. 2005. Harmful and
protective roles of neutrophils in sepsis. Shock 24:40–47.
23. Hotchkiss, R. S., and D. W. Nicholson. 2006. Apoptosis and caspases regu-
late death and inflammation in sepsis. Nat. Rev. Immunol. 6:813–822.
24. Hotchkiss, R. S., S. B. Osmon, K. C. Chang, T. H. Wagner, C. M. Coopersmith,
and I. E. Karl. 2005. Accelerated lymphocyte death in sepsis occurs by both the
death receptor and mitochondrial pathways. J. Immunol. 174:5110–5118.
25. Hotchkiss, R. S., P. E. Swanson, B. D. Freeman, K. W. Tinsley, J. P. Cobb,
G. M. Matuschak, T. G. Buchman, and I. E. Karl. 1999. Apoptotic cell death
in patients with sepsis, shock, and multiple organ dysfunction. Crit. Care
Med. 27:1230–1251.
26. Hotchkiss, R. S., P. E. Swanson, C. M. Knudson, K. C. Chang, J. P. Cobb,
D. F. Osborne, K. M. Zollner, T. G. Buchman, S. J. Korsmeyer, and I. E.
Karl. 1999. Overexpression of Bcl-2 in transgenic mice decreases apoptosis
and improves survival in sepsis. J. Immunol. 162:4148–4156.
27. Hotchkiss, R. S., K. W. Tinsley, P. E. Swanson, R. E. Schmieg, Jr., J. J. Hui,
K. C. Chang, D. F. Osborne, B. D. Freeman, J. P. Cobb, T. G. Buchman, and
I. E. Karl. 2001. Sepsis-induced apoptosis causes progressive profound depletion
of B and CD4 T lymphocytes in humans. J. Immunol. 166:6952–6963.
28. Kasten, K. R., H. S. Goetzman, M. R. Reid, A. M. Rasper, S. G. Adediran,
C. T. Robinson, C. M. Cave, J. S. Solomkin, A. B. Lentsch, J. A. Johannig-
man, and C. C. Caldwell. 2010. Divergent adaptive and innate immunolog-
ical responses are observed in humans following blunt trauma. BMC Immu-
nol. 11:4.
29. Kasten, K. R., J. Tschoep, H. S. Goetzman, L. G. England, J. R. Dattilo,
C. M. Cave, A. P. Seitz, D. A. Hildeman, and C. C. Caldwell. T cell activation
differentially mediates the host response to sepsis. Shock, in press.
30. Kasten, K. R., J. Tschop, S. G. Adediran, D. A. Hildeman, and C. C.
Caldwell. T cells are potent early mediators of the host response to sepsis.
Shock, in press.
31. Kopydlowski, K. M., C. A. Salkowski, M. J. Cody, N. van Rooijen, J. Major,
T. A. Hamilton, and S. N. Vogel. 1999. Regulation of macrophage chemokine
expression by lipopolysaccharide in vitro and in vivo. J. Immunol. 163:1537–
1544.
32. Leendertse, M., R. J. Willems, I. A. Giebelen, J. J. Roelofs, M. J. Bonten,
and T. van der Poll. 2009. Neutrophils are essential for rapid clearance of
Enterococcus faecium in mice. Infect. Immun. 77:485–491.
33. Le Tulzo, Y., C. Pangault, A. Gacouin, V. Guilloux, O. Tribut, L. Amiot, P.
Tattevin, R. Thomas, R. Fauchet, and B. Drenou. 2002. Early circulating
lymphocyte apoptosis in human septic shock is associated with poor out-
come. Shock 18:487–494.
34. Li, X., D. Klintman, Q. Liu, T. Sato, B. Jeppsson, and H. Thorlacius. 2004.
Critical role of CXC chemokines in endotoxemic liver injury in mice. J. Leu-
koc. Biol. 75:443–452.
35. Lin, A. A., P. K. Tripathi, A. Sholl, M. B. Jordan, and D. A. Hildeman. 2009.
Gamma interferon signaling in macrophage lineage cells regulates central
nervous system inflammation and chemokine production. J. Virol. 83:8604–
8615.
36. Liu, Y. J., V. Soumelis, N. Watanabe, T. Ito, Y. H. Wang, W. Malefyt Rde, M.
Omori, B. Zhou, and S. F. Ziegler. 2007. TSLP: an epithelial cell cytokine
that regulates T cell differentiation by conditioning dendritic cell maturation.
Annu. Rev. Immunol. 25:193–219.
37. Martignoni, A., J. Tschop, H. S. Goetzman, L. G. Choi, M. D. Reid, J. A.
Johannigman, A. B. Lentsch, and C. C. Caldwell. 2008. CD4-expressing cells
are early mediators of the innate immune system during sepsis. Shock 29:
591–597.
38. Martin, B., K. Hirota, D. J. Cua, B. Stockinger, and M. Veldhoen. 2009.
Interleukin-17-producing gammadelta T cells selectively expand in response
to pathogen products and environmental signals. Immunity 31:321–330.
39. Monneret, G., F. Venet, A. Pachot, and A. Lepape. 2008. Monitoring immune
dysfunctions in the septic patient: a new skin for the old ceremony. Mol.
Med. 14:64–78.
40. Pennington, D. J., D. Vermijlen, E. L. Wise, S. L. Clarke, R. E. Tigelaar, and
A. C. Hayday. 2005. The integration of conventional and unconventional T
cells that characterizes cell-mediated responses. Adv. Immunol. 87:27–59.
41. Polderman, K. H., and A. R. Girbes. 2004. Drug intervention trials in sepsis:
divergent results. Lancet 363:1721–1723.
42. Remick, D. G., G. R. Bolgos, J. Siddiqui, J. Shin, and J. A. Nemzek. 2002. Six
at six: interleukin-6 measured 6 h after the initiation of sepsis predicts
mortality over 3 days. Shock 17:463–467.
43. Roark, C. L., P. L. Simonian, A. P. Fontenot, W. K. Born, and R. L. O’Brien.
2008. Gammadelta T cells: an important source of IL-17. Curr. Opin. Im-
munol. 20:353–357.
44. Rollins, B. J. 1997. Chemokines. Blood 90:909–928.
45. Romagnani, P., F. Annunziato, E. Lazzeri, L. Cosmi, C. Beltrame, L. Lasa-
gni, G. Galli, M. Francalanci, R. Manetti, F. Marra, V. Vanini, E. Maggi,
and S. Romagnani. 2001. Interferon-inducible protein 10, monokine induced
by interferon gamma, and interferon-inducible T-cell alpha chemoattractant
are produced by thymic epithelial cells and attract T-cell receptor (TCR)
alphabeta CD8 single-positive T cells, TCRgammadelta T cells, and
natural killer-type cells in human thymus. Blood 97:601–607.
46. Rosenberg, S. A., C. Sportes, M. Ahmadzadeh, T. J. Fry, L. T. Ngo, S. L.
Schwarz, M. Stetler-Stevenson, K. E. Morton, S. A. Mavroukakis, M. Morre,
R. Buffet, C. L. Mackall, and R. E. Gress. 2006. IL-7 administration to
humans leads to expansion of CD8 and CD4 cells but a relative decrease
of CD4 T-regulatory cells. J. Immunother. 29:313–319.
47. Shelley, O., T. Murphy, H. Paterson, J. A. Mannick, and J. A. Lederer. 2003.
Interaction between the innate and adaptive immune systems is required to
survive sepsis and control inflammation after injury. Shock 20:123–129.
48. Solomkin, J. S., C. T. Robinson, C. M. Cave, B. Ehmer, and A. B. Lentsch.
2007. Alterations in membrane cholesterol cause mobilization of lipid rafts
from specific granules and prime human neutrophils for enhanced adher-
ence-dependent oxidant production. Shock 28:334–338.
49. Sportes, C., F. T. Hakim, S. A. Memon, H. Zhang, K. S. Chua, M. R. Brown,
T. A. Fleisher, M. C. Krumlauf, R. R. Babb, C. K. Chow, T. J. Fry, J. Engels,
R. Buffet, M. Morre, R. J. Amato, D. J. Venzon, R. Korngold, A. Pecora, R. E.
Gress, and C. L. Mackall. 2008. Administration of rhIL-7 in humans in-
creases in vivo TCR repertoire diversity by preferential expansion of naive T
cell subsets. J. Exp. Med. 205:1701–1714.
50. Sutton, C. E., S. J. Lalor, C. M. Sweeney, C. F. Brereton, E. C. Lavelle, and
K. H. Mills. 2009. Interleukin-1 and IL-23 induce innate IL-17 production
from gammadelta T cells, amplifying Th17 responses and autoimmunity.
Immunity 31:331–341.
51. Tanimoto, N., M. Terasawa, M. Nakamura, D. Kegai, N. Aoshima, Y. Koba-




arch 26, 2014 by W







yashi, and K. Nagata. 2007. Involvement of KC, MIP-2, and MCP-1 in
leukocyte infiltration following injection of necrotic cells into the peritoneal
cavity. Biochem. Biophys. Res. Commun. 361:533–536.
52. Tebo, J. M., H. S. Kim, J. Gao, D. A. Armstrong, and T. A. Hamilton. 1998.
Interleukin-10 suppresses IP-10 gene transcription by inhibiting the produc-
tion of class I interferon. Blood 92:4742–4749.
53. Thiel, M., C. C. Caldwell, S. Kreth, S. Kuboki, P. Chen, P. Smith, A. Ohta,
A. B. Lentsch, D. Lukashev, and M. V. Sitkovsky. 2007. Targeted deletion of
HIF-1alpha gene in T cells prevents their inhibition in hypoxic inflamed
tissues and improves septic mice survival. PLoS One 2:e853.
54. Tschop, J., A. Martignoni, H. S. Goetzman, L. G. Choi, Q. Wang, J. G. Noel,
C. K. Ogle, T. A. Pritts, J. A. Johannigman, A. B. Lentsch, and C. C.
Caldwell. 2008. Gammadelta T cells mitigate the organ injury and mortality
of sepsis. J. Leukoc. Biol. 83:581–588.
55. Unsinger, J., M. McGlynn, K. R. Kasten, A. S. Hoekzema, E. Watanabe, J. T.
Muenzer, J. S. McDonough, J. Tschoep, T. A. Ferguson, J. E. McDunn, M.
Morre, D. A. Hildeman, C. C. Caldwell, and R. S. Hotchkiss. 2010. IL-7
promotes T cell viability, trafficking, and functionality and improves survival
in sepsis. J. Immunol. 184:3768–3779.
56. Venet, F., F. Davin, C. Guignant, A. Larue, M. A. Cazalis, R. Darbon, C.
Allombert, B. Mougin, C. Malcus, F. Poitevin-Later, A. Lepape, and G.
Monneret. Early assessment of leukocyte alterations at diagnosis of septic
shock. Shock, in press.
57. Wang, S. D., K. J. Huang, Y. S. Lin, and H. Y. Lei. 1994. Sepsis-induced
apoptosis of the thymocytes in mice. J. Immunol. 152:5014–5021.
58. Weaver, C. T., R. D. Hatton, P. R. Mangan, and L. E. Harrington. 2007.
IL-17 family cytokines and the expanding diversity of effector T cell lineages.
Annu. Rev. Immunol. 25:821–852.
59. Wengner, A. M., S. C. Pitchford, R. C. Furze, and S. M. Rankin. 2008. The
coordinated action of G-CSF and ELR  CXC chemokines in neutrophil
mobilization during acute inflammation. Blood 111:42–49.
60. Wesche, D. E., J. L. Lomas-Neira, M. Perl, C. S. Chung, and A. Ayala. 2005.
Leukocyte apoptosis and its significance in sepsis and shock. J. Leukoc. Biol.
78:325–337.
61. Widney, D. P., Y. R. Xia, A. J. Lusis, and J. B. Smith. 2000. The murine
chemokine CXCL11 (IFN-inducible T-cell alpha chemoattractant) is an
IFN-gamma- and lipopolysaccharide-inducible glucocorticoid-attenuated re-
sponse gene expressed in lung and other tissues during endotoxemia. J. Im-
munol. 164:6322–6331.
62. Ye, P., F. H. Rodriguez, S. Kanaly, K. L. Stocking, J. Schurr, P. Schwarzen-
berger, P. Oliver, W. Huang, P. Zhang, J. Zhang, J. E. Shellito, G. J. Bagby,
S. Nelson, K. Charrier, J. J. Peschon, and J. K. Kolls. 2001. Requirement of
interleukin 17 receptor signaling for lung CXC chemokine and granulocyte
colony-stimulating factor expression, neutrophil recruitment, and host de-
fense. J. Exp. Med. 194:519–527.
Editor: J. N. Weiser




arch 26, 2014 by W
ashington University in St. Louis
http://iai.asm
.org/
D
ow
nloaded from
 
